MorphoSys is dedicated to the discovery, development and commercialization of innovative therapies for patients suffering from serious diseases, with a focus on cancer. Living up to the origin of our name - Metamorphosis - we have embarked on an ambitious transformation from a leading R&D company to a fully integrated biopharmaceutical company with an approval for a breakthrough cancer therapy.
Over the last two decades, MorphoSys forged partnerships with many of the leading global pharmaceutical companies. Together with our global partners, we have developed more than 100 product candidates, of which 27 are currently in clinical development - one of the broadest pipelines in the industry.
Headquartered in Planegg, near Munich, Germany, MorphoSys, including the fully owned U.S. subsidiary MorphoSys US Inc. in Boston, MA, has 600+ employees.
Learn MOR at www.morphosys.com or www.morphosys-us.com.